These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 32383785)

  • 21. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.
    Hoyer J; Vasileiou G; Uebe S; Wunderle M; Kraus C; Fasching PA; Thiel CT; Hartmann A; Beckmann MW; Lux MP; Reis A
    BMC Cancer; 2018 Sep; 18(1):926. PubMed ID: 30257646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.
    Balko JM; Giltnane JM; Wang K; Schwarz LJ; Young CD; Cook RS; Owens P; Sanders ME; Kuba MG; Sánchez V; Kurupi R; Moore PD; Pinto JA; Doimi FD; Gómez H; Horiuchi D; Goga A; Lehmann BD; Bauer JA; Pietenpol JA; Ross JS; Palmer GA; Yelensky R; Cronin M; Miller VA; Stephens PJ; Arteaga CL
    Cancer Discov; 2014 Feb; 4(2):232-45. PubMed ID: 24356096
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
    Brianese RC; Nakamura KDM; Almeida FGDSR; Ramalho RF; Barros BDF; Ferreira ENE; Formiga MNDC; de Andrade VP; de Lima VCC; Carraro DM
    Breast Cancer Res Treat; 2018 Feb; 167(3):803-814. PubMed ID: 29116469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
    Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
    Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarkers of DNA Repair and Related Pathways: Significance of Treatment in Triple-Negative Breast Cancer.
    Guo W; Lin L; He X; He F; Wang C; Chen N; Wang Y
    Crit Rev Oncog; 2017; 22(5-6):427-437. PubMed ID: 29604922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians.
    Ademuyiwa FO; Tao Y; Luo J; Weilbaecher K; Ma CX
    Breast Cancer Res Treat; 2017 Feb; 161(3):491-499. PubMed ID: 27915434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive Analysis of Differentially Expressed Profiles of lncRNAs/mRNAs and miRNAs with Associated ceRNA Networks in Triple-Negative Breast Cancer.
    Yang R; Xing L; Wang M; Chi H; Zhang L; Chen J
    Cell Physiol Biochem; 2018; 50(2):473-488. PubMed ID: 30308479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67.
    Jovanović B; Mayer IA; Mayer EL; Abramson VG; Bardia A; Sanders ME; Kuba MG; Estrada MV; Beeler JS; Shaver TM; Johnson KC; Sanchez V; Rosenbluth JM; Dillon PM; Forero-Torres A; Chang JC; Meszoely IM; Grau AM; Lehmann BD; Shyr Y; Sheng Q; Chen SC; Arteaga CL; Pietenpol JA
    Clin Cancer Res; 2017 Aug; 23(15):4035-4045. PubMed ID: 28270498
    [No Abstract]   [Full Text] [Related]  

  • 30. [Application value of DNA damage repair variants in adjuvant therapy of triple negative breast cancer].
    Wang X; Yue J; Kang YK; Gao SL; Yuan P
    Zhonghua Zhong Liu Za Zhi; 2023 Sep; 45(9):787-795. PubMed ID: 37805443
    [No Abstract]   [Full Text] [Related]  

  • 31. BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness.
    Domagala P; Hybiak J; Cybulski C; Lubinski J
    Int J Cancer; 2017 Apr; 140(7):1545-1550. PubMed ID: 27943282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.
    Toffoli S; Bar I; Abdel-Sater F; Delrée P; Hilbert P; Cavallin F; Moreau F; Van Criekinge W; Lacroix-Triki M; Campone M; Martin AL; Roché H; Machiels JP; Carrasco J; Canon JL
    Breast Cancer Res; 2014 Nov; 16(6):466. PubMed ID: 25416589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequent incidence of BARD1-truncating mutations in germline DNA from triple-negative breast cancer patients.
    De Brakeleer S; De Grève J; Desmedt C; Joris S; Sotiriou C; Piccart M; Pauwels I; Teugels E
    Clin Genet; 2016 Mar; 89(3):336-40. PubMed ID: 26010302
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences in molecular features of triple-negative breast cancers based on the age at diagnosis.
    Gulbahce HE; Bernard PS; Weltzien EK; Factor RE; Kushi LH; Caan BJ; Sweeney C
    Cancer; 2018 Dec; 124(24):4676-4684. PubMed ID: 30311638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor Mutation Burden and Immune Invasion Characteristics in Triple Negative Breast Cancer: Genome High-Throughput Data Analysis.
    Gao C; Li H; Liu C; Xu X; Zhuang J; Zhou C; Liu L; Feng F; Sun C
    Front Immunol; 2021; 12():650491. PubMed ID: 33968045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.
    Millis SZ; Gatalica Z; Winkler J; Vranic S; Kimbrough J; Reddy S; O'Shaughnessy JA
    Clin Breast Cancer; 2015 Dec; 15(6):473-481.e3. PubMed ID: 26051240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study.
    Guerini-Rocco E; Hodi Z; Piscuoglio S; Ng CK; Rakha EA; Schultheis AM; Marchiò C; da Cruz Paula A; De Filippo MR; Martelotto LG; De Mattos-Arruda L; Edelweiss M; Jungbluth AA; Fusco N; Norton L; Weigelt B; Ellis IO; Reis-Filho JS
    J Pathol; 2015 Oct; 237(2):166-78. PubMed ID: 26011570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
    Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
    Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Whole-exome sequencing and RNA sequencing analyses of acinic cell carcinomas of the breast.
    Beca F; Lee SSK; Pareja F; Da Cruz Paula A; Selenica P; Ferrando L; Gularte-Mérida R; Wen HY; Zhang H; Guerini-Rocco E; Rakha EA; Weigelt B; Reis-Filho JS
    Histopathology; 2019 Dec; 75(6):931-937. PubMed ID: 31361912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality.
    Papadimitriou M; Mountzios G; Papadimitriou CA
    Cancer Treat Rev; 2018 Jun; 67():34-44. PubMed ID: 29753961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.